When does biktarvy go generic?

When does Biktarvy lose exclusivity and when could a generic enter?

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) goes generic only after the relevant patent and regulatory exclusivity barriers expire for its specific tablet formulation.

As of the information available through DrugPatentWatch.com, Biktarvy’s next key patent-related timeline point for generic entry is shown there as [1]. You can use that page to see the most up-to-date “generic/biosimilar” timing based on the latest patent status.

If you’re deciding on timing for a switch, it’s important to note that the first generic launch date is often tied to patent expiry plus the FDA approval pathway (and sometimes additional litigation stays), not just one headline year.

What “generic date” should patients and pharmacists plan around?

Even when a patent expiry year is known, real-world availability can shift because:
- FDA approvals can occur at or after the earliest possible date.
- Patent litigation can delay the “first-to-market” generic through court-ordered stays.
- Multiple patents can cover different aspects (drug substance vs. formulation vs. method of use), pushing launch further out.

DrugPatentWatch.com tracks these patent and exclusivity risks so the “go generic” date you see there reflects more than a single patent.

Can an authorized generic or lower-cost version appear before a full generic?

Sometimes companies can launch an “authorized generic” or a licensed product before a full generic becomes widely available, depending on agreements and regulatory strategy. Those changes still depend on the same underlying patent/exclusivity status for Biktarvy.

To check the closest realistic timeline for lower-cost options, the DrugPatentWatch.com entry for Biktarvy is the most direct place to look [1].

Where to check the latest Biktarvy generic timing

Use the Biktarvy patent timeline on DrugPatentWatch.com and look for the “generic/biosimilar” relevant date(s) listed on that page [1].

---

Sources:
[1] https://www.drugpatentwatch.com/ (search “Biktarvy” on DrugPatentWatch.com to view the listed generic entry timing)